Charles River Laboratories International, Inc. (CRL) Valuation

Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of anima...

Charles River Laboratories International, Inc. (CRL) currently trades at a P/E ratio of 18.95 (historical range: 18.52–26.93, median: 22.64), placing it at the 3th percentile — cheap relative to its history, P/S ratio of 3.57 (range: 1.26–3.66, 99th percentile — expensive relative to its history), EV/EBITDA of 140.67 (range: 28.74–523.10, 86th percentile).

Charles River Laboratories International, Inc. appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.

Historical Valuation Metrics

MetricCurrentMinMedianMaxPercentileAssessment
P/E Ratio18.9518.5222.6426.933thcheap relative to its history
P/S Ratio3.571.262.173.6699thexpensive relative to its history
EV/EBITDA140.6728.7458.81523.1086thexpensive relative to its history
FCF Yield0.070.010.040.0797thcheap relative to its history
Current Price: $282.34
Market Cap: $13.5B
Sector: Healthcare